样式: 排序: IF: - GO 导出 标记为已读
-
Safety of biologic agents for the management of rheumatic diseases during pregnancy. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-03-11 Jonathan D D'Gama, Bonnie L Bermas
To discuss the current understanding regarding the use of biologic therapeutics in pregnancy.
-
Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-03-06 Kevin D Deane
This review discusses updates in the prediction and prevention of future rheumatoid arthritis (RA).
-
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-03-01 Yuting Qin, Jianyang Ma, Carola G Vinuesa
This review aims to provide an overview of the genes and molecular pathways involved in monogenic lupus, the implications for genome diagnosis, and the potential therapies targeting these molecular mechanisms.
-
Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-02-27 Günter Steiner, René E M Toes
RA is characterized by the presence of autoantibodies among which rheumatoid factors (RFs) and antimodified protein antibodies (AMPA) are serological hallmarks of the disease. In recent years, several novel insights into the biology, immunogenetics and clinical relevance of these autoantibodies have been obtained, which deserve to be discussed in more detail.
-
Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-02-26 Elena Myasoedova, Eric L Matteson
To discuss changes in epidemiology, recent advances in understanding of the pathogenesis and management of selected extraarticular manifestations of rheumatoid arthritis (ExRA).
-
Management of postinfectious inflammatory arthritis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-02-22 Hailey Baker, J Kennedy Amaral, Robert T Schoen
Postinfectious inflammatory arthritis can result from various pathogens, including bacteria, viruses, fungi, and parasites. Prompt identification and treatment of acute infection is vital, but some cases progress to chronic arthritis despite successful treatment of infection. Postinfectious inflammatory arthritis varies from mild, self-limited arthralgia to severe, refractory arthritis, necessitating
-
Cardiovascular complications of rheumatoid arthritis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-02-12 Elizabeth Park, Joan Bathon
Rheumatoid arthritis (RA) patients remain at higher cardiovascular (CV) risk compared to non-RA patients, driven by accelerated atherosclerosis, leading to plaque rupture and acute CV events (CVE), including heart failure (HF). It has been hypothesized that chronic inflammation is the main driving force behind such outcomes. We summarize the current evidence supporting this hypothesis, focusing on
-
Emerging biologic therapies for systemic lupus erythematosus. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2024-02-02 Hiroshi Kato, J Michelle Kahlenberg
The approval of belimumab and anifrolumab has expanded the scope of treatment for systemic lupus erythematosus (SLE) patients. However, many patients remain refractory to currently available therapies and suffer from drug toxicities. This review will discuss approved and target-specific therapeutics in development that bring hope for better SLE treatments.
-
Health disparities in gout. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-12-26 Lindsay N Helget, Ted R Mikuls
Gout, the most common type of inflammatory arthritis in the world, is characterized by painful episodes of arthritis linked by asymptomatic intercritical periods of hyperuricemia. Once characterized as a disease of wealthy white men, contemporary evidence demonstrates gout disproportionately afflicts racial/ethnic minorities, Indigenous populations and other underrepresented groups leading to significant
-
Cardiovascular disease in spondyloarthritis: a narrative review of risk factors and the effect of treatments. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-12-21 Rouhin Sen, Liron Caplan, Maria I Danila
This review summarizes the recent evidence available regarding the epidemiology of cardiovascular disease in spondyloarthritis (SpA), including the effect of disease modifying drugs on cardiovascular risk.
-
Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-12-21 Kaia Barth, Harsimrat Gill, Namrata Singh
The landscape for treatment of rheumatic diseases is ever evolving, with several new drugs recently approved across diseases and more in the pipeline. This timely review aims to highlight the latest literature on long-term safety profiles of salient established and emerging biologic (b) and targeted synthetic (ts) disease modifying antirheumatic drugs (DMARDs).
-
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-12-18 Rohith Appalaneni, Nikhila Achanta, Chandra Mohan
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized cancer treatment by harnessing the immune system's power to target malignancies. CD19, a B-cell surface antigen, a key target for CAR-T cell therapy in hematological malignancies, displayed remarkable clinical responses. Recently, there has been a growing interest in exploring the application of CD19 CAR-T cell therapy beyond oncology
-
Vaccination updates and special considerations for systemic lupus erythematosus patients. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-11-17 Jammie Law, Cristina Sorrento, Amit Saxena
We review the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, and potentially respiratory syncytial virus (RSV) vaccine in the future.
-
Microbiome dynamics in rheumatic diseases. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-11-17 Yiqing Wang, Zijun Wang, Qianjin Lu
Rheumatic disease are characterized by their autoimmune nature, frequently affecting joints, bones, muscles, blood vessels, and connective tissues. The onset of these conditions typically unfolds gradually and subtly. It is noteworthy that individuals with rheumatic diseases often experience shifts in their microbiome, specifically on mucosal surfaces. The purpose of this review is to delve into the
-
Diagnosis and management of primary heart involvement in systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-11-09 Giacomo De Luca, Marco Matucci-Cerinic, Sophie I Mavrogeni
In systemic sclerosis (SSc) primary heart involvement (pHI) is frequent, even though often unrecognized due to its occult nature and to the lack of a specific diagnostic algorithm. The purpose of this review is to report the state of the art of the evidence in the current literature, as well as the overall diagnostic modalities and therapeutic strategies for primary heart involvement in SSc.
-
Recent findings in idiopathic inflammatory myopathies with potential diagnostic and therapeutic implications. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-11-01 Anna Ghirardello,Chiara Franco,Mariele Gatto
-
Updates on translational and clinical research in systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-11-01 Shervin Assassi
-
T lymphocytes-related cell network in the pathogenesis of juvenile idiopathic arthritis: a key point for personalized treatment. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-10-27 Alessio Mazzoni,Francesco Annunziato,Laura Maggi
PURPOSE OF REVIEW Juvenile idiopathic arthritis (JIA) is a heterogeneous group of arthritis of unknown origin occurring in children under 16 years of age and persisting for at least 6 weeks. Given that JIA is an inflammatory disorder, treatment strategies, including also biologicals, are focused on suppressing excessive inflammation. The finding that different patients display different responses to
-
Epidemiology of osteoarthritis: literature update 2022-2023. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-10-19 Mary Catherine C Minnig, Yvonne M Golightly, Amanda E Nelson
This review highlights recently published studies on osteoarthritis (OA) epidemiology, including topics related to understudied populations and joints, imaging, and advancements in artificial intelligence (AI) methods.
-
Calcinosis in systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-10-11 Srijana Davuluri, Christian Lood, Lorinda Chung
To provide updated information on the prevalence, pathogenesis, diagnostics, and therapeutics of calcinosis cutis associated with systemic sclerosis (SSc).
-
Epidemiology of systemic vasculitis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-10-06 Yesim Ozguler, Sinem Nihal Esatoglu, Gulen Hatemi
Epidemiology of vasculitides exhibit geographic variation and data from some parts of the world are still scarce. Increased recognition of these rare diseases and improvement in diagnosis and patient care may lead to changes in their epidemiology. In this review, we aimed to highlight the most recent work on the epidemiology of systemic vasculitis.
-
Current treatment approach to AAV-associated vasculitis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-27 Yusuf Yazici
This review will attempt to summarize the most potentially impactful new data on the way ANCA-associated vasculitis (AAV) is diagnosed, treated, and monitored.
-
Cluster analysis as a clinical and research tool in Behçet's syndrome. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-18 Ufuk Ilgen
PURPOSE OF REVIEW The purpose of this review was to comprehensively summarize recent phenotype research findings in Behçet's syndrome. RECENT FINDINGS Cluster analysis has recently been employed as a phenotype research tool in Behçet's syndrome. Studies reported different clustering patterns caused by biological variation and some degree of artificial heterogeneity. However, some clusters were more
-
Large language models and the future of rheumatology: assessing impact and emerging opportunities. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-18 Insa Mannstadt,Bella Mehta
PURPOSE OF REVIEW Large language models (LLMs) have grown rapidly in size and capabilities as more training data and compute power has become available. Since the release of ChatGPT in late 2022, there has been growing interest and exploration around potential applications of LLM technology. Numerous examples and pilot studies demonstrating the capabilities of these tools have emerged across several
-
Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-18 Ariane L Herrick,Christopher P Denton
PURPOSE OF REVIEW This review gives an update on enrichment strategies for clinical trials in patients with systemic sclerosis (SSc) in two contexts - skin fibrosis in early diffuse cutaneous disease, and SSc-related interstitial lung disease (ILD) - focusing on reports from the last 18 months. Lessons have been learnt from recent studies, making this review timely. RECENT FINDINGS Recent trials have
-
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-13 Elena Neumann, Corinna Heck, Ulf Müller-Ladner
Synovial fibroblasts are the central cells of connective tissue homeostasis. In rheumatoid arthritis (RA) tissue, synovial fibroblasts are activated because of the proinflammatory environment very early in the disease. Epigenetic alterations in RASF result in a permanently activated stage, and activated RASF are involved in many processes of RA pathophysiology. Therefore, several recent findings of
-
Janus kinase inhibitors: efficacy and safety. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-08 Stanley Cohen, Virginia Reddy
Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested safety concerns with the JAKi, which will be reviewed.
-
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-08 Ann-Christin Pecher, Melanie Henes, Joerg C Henes
Antineutrophil cytoplasmatic antibody associated vasculitis (AAV) usually manifests after age fifty, thus making it very rare during reproductive age. Although rare, AAV, particularly eosinophilic granulomatosis with polyangiitis, can manifest at a younger age. AAV can also appear for the first time during pregnancy.
-
New therapies in anti-MDA5 antibody-positive dermatomyositis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-08 Masahiro Yasui, Taro Iwamoto, Shunsuke Furuta
This review focuses on treatments for anti-MDA5 antibody-positive dermatomyositis (MDA5-DM), which is a subgroup of dermatomyositis and characterized by frequent rapidly progressive interstitial lung disease and the high mortality rate. Despite conventional immunosuppressive therapies, there are still refractory cases. Newer treatment options are needed.
-
The contribution of endothelial cells to tissue fibrosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-07 Eloisa Romano,Irene Rosa,Bianca Saveria Fioretto,Mirko Manetti
PURPOSE OF REVIEW Tissue fibrosis is an increasingly prevalent condition associated with various diseases and heavily impacting on global morbidity and mortality rates. Growing evidence indicates that common cellular and molecular mechanisms may drive fibrosis of diverse cause and affecting different organs. The scope of this review is to highlight recent findings in support for an important role of
-
Update of muscle imaging in myositis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-09-01 Ai Lyn Tan, Andrea Di Matteo, Richard J Wakefield, John Biglands
Imaging techniques such as MRI, ultrasound and PET/computed tomography (CT) have roles in the detection, diagnosis and management of myositis or idiopathic inflammatory myopathy (IIM). Imaging research has also provided valuable knowledge in the understanding of the pathology of IIM. This review explores the latest advancements of these imaging modalities in IIM.
-
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-30 Laura Ross, Mandana Nikpour
The aim of this study was to summarize the composite outcome measures available to assess disease damage, severity and treatment response in systemic sclerosis (SSc).
-
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-30 Alain Lescoat, Hiroshi Kato, John Varga
Although two targeted therapies have received recent approval for systemic sclerosis (SSc)-associated interstitial lung disease, they do not show major disease-modifying activity, highlighting the need for novel therapies and innovative paradigms. To that end, cellular therapies may represent a new opportunity for the treatment of SSc. The purpose of this review is to provide an up-to-date overview
-
Myopathy in systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-23 Caoilfhionn M Connolly, Julie J Paik
Systemic sclerosis associated myopathy (SSc-AM) is a complex, heterogenous disease that is associated with poor outcomes. SSc-AM lacks a clear definition, and continues to be poorly recognized. The purpose of this review is to provide a contemporary overview of the clinical, serological and pathophysiologic findings in SSc-AM to guide optimal recognition and management of this challenging disease manifestation
-
Methods for objective assessment of skin involvement in systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-22 Ruhani Desai, Harshdeep Chawla, Kirill Larin, Shervin Assassi
Skin fibrosis is the most prominent disease manifestation of systemic sclerosis (SSc). Although the treatment for other SSc manifestations has expanded over the years, there is limited progress in identifying effective treatment options for SSc skin involvement. This is in part due to limitations in the utilized outcome measures for assessment of skin fibrosis. This review focuses on different emerging
-
Animal models in systemic sclerosis: an update. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-22 Xiongjie Bi, Tingting Mills, Minghua Wu
Systemic sclerosis (SSc) is a multisystem autoimmune connective tissue disease characterized by early inflammation followed by excessive fibrosis in the skin and internal organs. Enhancing our comprehension of SSc pathogenesis is essential to develop effective therapeutic strategies. Animal models that mimic one or more aspects of SSc have been proven to be a valuable resource for investigating disease
-
Raynaud phenomenon and microvasculopathy in systemic sclerosis: multi-modality imaging for diagnosis and evaluation. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-13 George Markousis-Mavrogenis,Vasiliki-Kalliopi Bournia,Petros P Sfikakis,Sophie I Mavrogeni
PURPOSE OF REVIEW To describe the clinical significance of and the diagnostic approach to Raynaud phenomenon (RP) in the peripheral extremities and the heart. RECENT FINDINGS Nailfold capillaroscopy has recently been standardized in an expert consensus paper. Abnormal capillaroscopy in combination with specific autoantibody profiles and clinical signs are highly predictive of progression of RP to systemic
-
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-13 Federico Pettorossi,Michela Gasparotto,Anna Ghirardello,Chiara Franco,Giulio Ceolotto,Alessandra Giannella,Luca Iaccarino,Elisabetta Zanatta,Andrea Doria,Mariele Gatto
PURPOSE OF REVIEW Idiopathic inflammatory myopathies (IIMs) are a group of rare autoimmune disorders characterized by muscle weakness and inflammation. MicroRNAs (miRNAs) are the main class of small noncoding RNAs regulating a wide range of physiological and pathological processes and play a role in mediating autoimmunity and inflammation. In this review, we summarize the latest knowledge on the role
-
Targeting B cells for treatment of systemic sclerosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-08-04 Hitoshi Terui, Yuichiro Segawa, Yoshihide Asano
The pathogenesis of systemic sclerosis (SSc) has been linked to dysfunctional B cells as demonstrated in previous research. This review aims to show the evidence and ongoing clinical trials of B cell-targeted therapy and overview the various aspects of B cell involvement in SSc.
-
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-27 May Y Choi,Minoru Satoh,Marvin J Fritzler
-
Exploring challenges in the management and treatment of inclusion body myositis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-26 Michael P Skolka, Elie Naddaf
This review provides an overview of the management and treatment landscape of inclusion body myositis (IBM), while highlighting the current challenges and future directions.
-
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-25 Yasushi Kawaguchi, Masataka Kuwana
In patients with systemic sclerosis (SSc), vascular manifestations precede skin and organ fibrosis. There is increasing evidence demonstrating a pathogenic link between early vascular injury and subsequent development of tissue fibrosis.
-
What is PFAPA syndrome? Genetic clues about the pathogenesis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-17 Kalpana Manthiram
PURPOSE OF REVIEW Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in childhood. Recent studies report genetic susceptibility variants for PFAPA syndrome and the efficacy of tonsillectomy in a broader cohort of patients with recurrent stereotypical fever. In this review, we highlight the findings of these studies and
-
Medium-vessel and large-vessel vasculitis in children. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-11 Christiaan Scott, Raphaella Stander, Frank Phoya
This article serves as an up-to-date examination of the latest findings in the field of paediatric large-vessel and medium-vessel vasculitis.
-
Update on autoinflammatory diseases. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-07 Kosar Asna Ashari, Jonathan S Hausmann, Fatma Dedeoglu
Although the concept of systemic autoinflammatory diseases (SAIDs) is still very young, our knowledge about them is exponentially growing. In the current review, we aim to discuss novel SAIDs and autoinflammatory pathways discovered in the last couple of years.
-
Update on treatment responses and outcome measure development in chronic nonbacterial osteomyelitis (CNO). Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-07-07 Shwetha Ramachandran, Yongdong Zhao, Polly J Ferguson
To review recent trends in treatment and recent progress in developing outcome measures needed for chronic nonbacterial osteomyelitis (CNO) clinical trials.
-
Challenges in treating juvenile idiopathic arthritis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-06-20 Marinka Twilt, Peter Stoustrup, Dax Rumsey
Juvenile idiopathic arthritis (JIA) diagnosis and classification is currently still based on clinical presentation and general laboratory tests. Some joints such as the temporomandibular joint (TMJ) and sacroiliac (SI) are hard to assess and define as actively inflamed based on clinical examination. This review addresses these difficult to assess joints and provides the latest evidence for diagnosis
-
The impact of dietary interventions in psoriatic arthritis. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-17 Ajesh B Maharaj, Lihi Eder, Alexis Ogdie
Psoriatic arthritis (PsA) is a common form of inflammatory arthritis that affects people with psoriasis. Both psoriasis and PsA are associated with metabolic diseases including obesity, hypertension, hyperlipidaemia, diabetes mellitus, fatty liver disease, and cardiovascular disease including myocardial infarction. Dietary interventions for psoriatic disease have been of great interest, particularly
-
New developments related to lung complications in pediatric rheumatic disease Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-05 Shipra Rai, Grant S. Schulert, Christopher Towe
Purpose of review While substantial progress has been made understanding lung disease in adult patients with rheumatic disease, pediatric lung disease has not been well addressed. Several recent studies provide new insights into diagnosis, management and treatment of lung disease in children with rheumatic disease. Recent findings Building on previous research, newly diagnosed patients may have abnormalities
-
When to stop medication in juvenile idiopathic arthritis Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-04 Dori Abel, Pamela F. Weiss
Purpose of review Disease-modifying antirheumatic drugs (DMARDs) have dramatically improved patient outcomes in juvenile idiopathic arthritis (JIA). However, these medications may also result in physical, psychologic, and economic burden, which must be balanced with risk of flare off treatment. Although some children remain in remission after medication discontinuation, evidence is sparse for if,
-
Evidence in support of the bone marrow as the primary lesion in axial spondyloarthritis Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-04-28 Walter P. Maksymowych
Purpose of review Over the past several decades, the concept that the primary lesion accounting for the development of axSpA is an enthesopathy has been widely accepted. However, the hallmark abnormality of axSpA occurs in the sacroiliac joint at the interface of cartilage and bone at a location remote from any anatomical enthesis. Both imaging and histopathological data from the sacroiliac joint
-
Human leucocyte antigen-B27 testing in clinical practice: a global perspective. Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-04-28 Nelly Ziade
The association between human leucocyte antigen (HLA)-B27 and spondyloarthritis (SpA) was described half a century ago. New insights about pathophysiologic pathways and their role in bone formation were reported in recent years and will be discussed in this review.
-
Go or no-go for treat-to-target in axial spondyloarthritis? Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-04-26 Casper Webers, Marin Been, Astrid van Tubergen
Purpose of review For almost a decade, treat-to-target (T2T) has been advocated as a management strategy for axial spondyloarthritis (axSpA), despite a lack of trial evidence. Recently, the first and only published T2T trial in axSpA did not meet its primary endpoint. The purpose of this review is to discuss whether we should continue with a T2T approach in axSpA and to describe some experiences with
-
Imaging in pediatric spondyloarthritis Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-04-17 Hallie A. Carol, Nancy A. Chauvin, Pamela F. Weiss
Purpose of review Imaging is used in the diagnosis of peripheral and axial disease in juvenile spondyloarthritis (JSpA). Imaging of the joints and entheses in children and adolescents can be challenging for those unfamiliar with the appearance of the maturing skeleton. These differences are key for rheumatologists and radiologists to be aware of. Recent findings In youth, skeletal variation during
-
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-04-10 Ian Mantel, Miriam R. Fein, Laura T. Donlin
Purpose of review To summarize recently discovered novel cell states in rheumatoid arthritis (RA) synovium that could have important implications for disease treatment. Recent findings The use of multiomic technologies, including single-cell and spatial transcriptomics and mass cytometry, has led to the discovery of several novel cell states, which could have important implications for the treatment
-
Tocilizumab in giant cell arteritis: an update for the clinician Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-01 Julia A. Ford, Danya Gewurz, Ora Gewurz-Singer
Purpose of review The recent approval of tocilizumab (TCZ) for the treatment of giant cell arteritis (GCA) has changed the landscape for management of this disease. Herein, we review recent literature addressing practical questions for the clinician regarding the use of TCZ in GCA. We evaluate efficacy of TCZ across different disease phenotypes, optimal dosing and formulation, treatment-related toxicity
-
Rheumatologic immune checkpoint inhibitor-related adverse events Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-01 Melissa Defoe, Bonnie L. Bermas
Purpose of review Immune check point inhibitors (ICIs) are a unique class of cancer treatments that harness the body's innate antitumor response. Although these medications have transformed oncology care, they also lead to generalized immune activation that can result in toxicities across a spectrum of organ systems called immune-related adverse events. This article reviews the most common rheumatologic
-
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-01 Amala Ambati, Jason S. Knight, Yu Zuo
Purpose of review Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types. Recent findings APS represents a disease spectrum. Although thrombosis
-
Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-01 Katherine Chakrabarti, W. Joseph McCune
Purpose of review This review seeks to summarize the literature relevant to the treatment of glucocorticoid-induced osteoporosis in premenopausal women; an issue commonly encountered by rheumatologists and yet lacking good clinical practice guidelines. Recent findings Although most of the relevant literature on osteoporosis includes postmenopausal women only, data from both randomized controlled
-
Fibromyalgia and centralized pain in the rheumatoid arthritis patient Curr. Opin. Rheumatol. (IF 5.1) Pub Date : 2023-05-01 Deeba Minhas, Anne Murphy, Daniel J. Clauw
Purpose of review Individuals with rheumatoid arthritis (RA) have traditionally been characterized as having nociceptive pain, leading to the assumption that effective immunosuppression should be enough to provide effective pain management. However, despite therapeutic advancements providing excellent control of inflammation, patients continue to have significant pain and fatigue. The presence of